First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro

Thomas Lund, Kent Søe, Niels Abildgaard, Patrick Garnero, Per T Pedersen, Tina Ormstrup, Jean-Marie Delaissé, Torben Plesner

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

OBJECTIVES: The aim of the study was to investigate the effect of bortezomib on osteoblast proliferation and differentiation, as well as on bone matrix deposition for the first time in bisphosphonate-naïve, previously untreated patients with myeloma. METHODS: Twenty newly diagnosed patients received four cycles of bortezomib treatment, initially as monotherapy and then combined with a glucocorticoid from cycle two to four. Bone remodeling markers were monitored closely during treatment. Furthermore, the effects of bortezomib and a glucocorticoid on immature and mature osteoblasts were also studied in vitro. RESULTS: Treatment with bortezomib caused a significant increase in bone-specific alkaline phosphatase and pro-collagen type I N-terminal propeptide, a novel bone formation marker. The addition of a glucocorticoid resulted in a transient decrease in collagen deposition. In vitro bortezomib induced osteoblast proliferation and differentiation. Differentiation but not proliferation was inhibited by glucocorticoid treatment. CONCLUSIONS: Bortezomib used as first-line treatment significantly increased collagen deposition in patients with multiple myeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy. The potential bone-healing properties of single-agent bortezomib are currently being explored in a clinical study in patients who have undergone high-dose therapy and autologous stem cell transplantation.
Original languageEnglish
JournalEuropean Journal of Haematology
Volume85
Issue number4
Pages (from-to)290-9
Number of pages10
ISSN0902-4441
DOIs
Publication statusPublished - 1. Oct 2010

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Boronic Acids
  • Cell Differentiation
  • Cell Proliferation
  • Cells, Cultured
  • Female
  • Glucocorticoids
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Osteoblasts
  • Osteogenesis
  • Osteolysis
  • Pyrazines

Fingerprint Dive into the research topics of 'First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro'. Together they form a unique fingerprint.

Cite this